retatrutide type 2 diabetes phase 2 results 2024 2025 Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released trial demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished The MariTide phase 2 trial
Description
Because the insulin glargine/lixisenatide FRC was used much more frequently than lixisenatide alone (99% insulin glargine/lixisenatide FRC vs
Is it because they are spending more on GLP1s and discretionary income decreases
GLP-1 receptor agonists: gastric emptying, procedures, and pancreatic safety
If necessary, they may adjust your Wegovy treatment plan
